Early and midterm risk of coronary allograft vasculopathy in patients bridged to orthotopic heart transplantation with ventricular assist devices

Transplantation

Volumn 79, Issue 9, 2005, Pages 1175-1179

  Gonzalez Stawinski, Gonzalo V ^a   Cook, Daniel J ^a   Chang, Albert S Y ^a   Atik, Fernando ^a   Navia, Jose L ^a   Banbury, Michael ^a   Roselli, Eric ^a   Young, James B ^a   Starling, Randall A ^a   Smedira, Nicholas G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Allograft; Coronary; Vasculopathy; Ventricular assist devices

Indexed keywords

ANTIBODY; CYTOTOXIC PANEL REACTIVE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOASSAY; MALE; ORGAN DONOR; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; T LYMPHOCYTE;

B-LYMPHOCYTES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20844448046     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200505150-00041     Document Type: Conference Paper

References (30)

1. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80: III100.
2. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827.
3. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 2000; 1: 166.
4. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant 2000; 19: 167.
5. Sijpkens YW, Doxiadis, II, van Kemenade FJ, et al. Chronic rejection with or without transplant vasculopathy. Clin Transplant 2003; 17: 163.
6. Hosenpud JD, Edwards EB, Lin HM, Daily OP. Influence of HLA matching on thoracic transplant outcomes. An analysis from the UNOS/ISHLT Thoracic Registry. Circulation 1996; 94: 170.
7. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11: S90.
8. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
9. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J 1995; 129: 791.
10. Tilney NL, Paz D, Ames J, et al. Ischemia-reperfusion injury. Transplant Proc 2001; 33: 843.
11. Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 1990; 4: 309.
12. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345: 1435.
13. Navia JL, McCarthy PM, Hoercher KJ, et al. Do left ventricular assist device (LVAD) bridge-to-transplantation outcomes predict the results of permanent LVAD implantation? Ann Thorac Surg 2002; 74: 2051.
14. Ma H, Hammond EH, Taylor DO, et al. The repetitive histologic pattern of vascular cardiac allograft rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Transplantation 1996; 62: 205.
15. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786.
16. Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 1180.
17. Iwaki Y, Cook DJ, Terasaki PI, et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 1987; 19: 764.
18. Cook DJ, Klingman LL, Koo AP, et al. Quantitative flow cytometry cross-matching for precise measurement of donor-specific alloreactivity. Transplant Proc 1994; 26: 2866.
19. Hurley JP, Cook DJ, McCarthy PM, et al. Flow cytometry crossmatching: a method for monitoring antidonor antibodies in heart transplant recipients. Transplant Proc 1995; 27: 1301.
20. Billingham ME, Gary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
21. Hammond EH, Hansen JK, Spenser LS, et al. Immunofluorescence of endomyocardial biopsy specimens: methods and interpretation. J Heart Lung Transplant 1993; 12: s113.
22. Morgan JA, John R, Rao V, et al. Bridging to transplant with the Heart-Mate left ventricular assist device: The Columbia Presbyterian 12-year experience. J Thorac Cardiovasc Surg 2004; 127: 1309.
23. Schmid C, Welp H, Klotz S, et al. Outcome of patients surviving to heart transplantation after being mechanically bridged for more than 100 days. J Heart Lung Transplant 2003; 22: 1054.
24. Gammie JS, Edwards LB, Griffith BP, et al. Optimal timing of cardiac transplantation after ventricular assist device implantations. J Thorac Cardiovasc Surg 2004; 127: 1789.
25. Itescu S, Schuster M, Burke E, et al. Immunobiologic consequences of assist devices. Cardiol Clin 2003; 21: 119.
26. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II229.
27. Mehra MR, Stapleton DD, Ventura HO, et al. Influence of donor and recipient gender on cardiac allograft vasculopathy. An intravascular ultrasound study. Circulation 1994; 90: 1178.
28. Yamani MH, Lauer MS, Starling RC, et al. Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. Am J Transplantation 2004; 4: 257.
29. Gonzalez-Stawinski GV, McCarthty PM, Cook DJ, et al. The risk of coronary transplant vasculopathy in patients bridged with a ventricular assist device. Transplantation 2004; 78: 135.
30. Kaplon RJ, Kapadia SR, Smedira NG, et al. Does LVAD bridging-to- transplantation increase graft vasculopathy? J Heart Lung Transplant 1999; 18: 63.